Treatment and prognosis of pT1N0M0 Luminal B-like breast cancer

摘 要
目的:分析pT1N0M0期Luminal B样乳腺癌的临床病理特征、治疗方法及预后情况。 方法:收集2010年1月—2013年1月于天津医科大学肿瘤医院行手术治疗的300例pT1N0M0期Luminal B样乳腺癌患者的资料。采用χ2检验进行临床病理资料之间的比较,Kaplan-Meier法分析患者的生存情况,log-rank检验行单因素分析,COX比例风险回归模型进行预后的多因素分析。 结果:300例pT1N0M0期Luminal B样乳腺癌患者中,pT1aN0M0期24例(8%),pT1bN0M0期115例(38.3%),pT1cN0M0期161例(53.7%)。χ2检验分析结果显示,组织学分级与肿瘤大小相关(P=0.004)。单因素分析结果显示,发病年龄、组织学分级、人表皮生长因子受体2(human epidermal growth factor receptor-2,HER-2)表达、增殖细胞核相关抗原Ki-67阳性标记指数及化疗对患者的5年无疾病生存率有影响(P值均<0.05);HER-2表达状态与患者的5年总生存率相关(P<0.05)。多因素分析显示,组织学分级(P=0.048)、是否化疗(P=0.046)、HER-2表达状态(P=0.001)和Ki-67高低(P=0.002)是影响患者5年无病生存率的独立因素。进一步分析化疗方案与预后的关系,结果显示紫杉类/蒽环类单药化疗组与紫杉类联合蒽环类化疗组相比,pT1a-bN0M0期患者的5年无病生存率和总生存率无明显差异(P值均>0.05),而pT1cN0M0期患者紫杉类联合蒽环类化疗组的5年无病生存率明显优于紫杉类/蒽环类单药化疗组(P=0.042),但5年总生存率无明显差异(P=0.711)。 结论:术后辅助化疗可以改善pT1N0M0期Luminal B样乳腺癌患者的预后。对pT1a-bN0M0期患者可以给予紫杉类/蒽环类单药为主的化疗方案,而对pT1cN0M0期患者给予紫杉类联合蒽环类方案化疗预后更好。






Abstract
Objective: To analyze the clinicopathological characteristics, treatment and prognosis of Luminal B-like breast cancer in pT1N0M0 stage. Methods: The data of 300 patients with stage pT1N0M0 Luminal B-like breast cancer who underwent surgery in Tianjin Medical University Cancer Institute and Hospital from January 2010 to January 2013 were collected. The clinicopathological characteristics, treatment and prognosis were retrospectively analyzed by using the statistical methods such as χ2 test, univariate analysis, COX multivariate analysis, Kaplan-Meier and so on. Results: In 300 cases of breast cancer, there were 24 cases (8%) in pT1aN0M0 stage, 115 cases (38.3%) in pT1bN0M0 stage, and 161 cases (53.7%) in pT1cN0M0 stage. Intergroup analysis (χ2 test) showed that only histological grade was related to tumor size (P = 0.004). Univariate analysis showed that age, histological grade, human epidermal growth factor receptor-2 (HER-2) expression, Ki-67 expression and chemotherapy had an effect on the five-year disease-free survival (DFS) of patients (all P < 0.05), and HER-2 was associated with five-year overall survival (OS) rate (P < 0.05). Multivariate analysis showed that histological grade (P = 0.048), chemotherapy (P = 0.046), HER-2 (P = 0.001) status and Ki-67 expression (P = 0.002) were independent factors of five-year DFS rate of the patients. The relationship between chemotherapy regimens and prognosis was further analyzed, and the results showed that five-year DFS rate and OS rate of the patients in pT1a-bN0M0 stage had no significant difference between taxane/anthracycline alone chemotherapy group and taxane combined with anthracycline group (both P > 0.05). For the patients in pT1cN0M0, the five-year DFS rate in taxane combined with anthracycline chemotherapy group was significantly higher than that in taxane/anthracycline alone chemotherapy group (P = 0.042), but the five-year OS rate was not significant different between the two groups (P = 0.711). Conclusion: Postoperative adjuvant chemotherapy can improve the prognosis of patients with stage pT1N0M0 Luminal B-like breast cancer. The patients in pT1a-bN0M0 stage may be given taxanes/anthraquinones chemotherapy for reducing overtreatment. For the patients in pT1cN0M0 stage, the prognosis will be better when the taxane combined with anthracycline chemotherapy is given.
中图分类号 R737.9 DOI 10.3781/j.issn.1000-7431.2018.33.258
所属栏目 临床研究
基金项目
收稿日期 2018/4/13
修改稿日期 2018/6/5
网络出版日期

作者单位点击查看

引用该论文: WANG Shixia,YANG Yanfang,LIU Jun. Treatment and prognosis of pT1N0M0 Luminal B-like breast cancer[J]. Tumor, 2018, 38(7): 689~696
王世霞,杨艳芳,刘 君. pT1N0M0期Luminal B样乳腺癌的治疗及预后分析[J]. 肿瘤, 2018, 38(7): 689~696
共有人对该论文发表了看法,其中:
人认为该论文很差
人认为该论文较差
人认为该论文一般
人认为该论文较好
人认为该论文很好






参考文献
【1】FITZMAURICE C, DICKER D, PAIN A, et al. The global burden of cancer 2013[J]. Jama Oncology, 2015, 1(4):505-527.
【2】ZHENG S, BAI JQ, LI J, et al. The pathologic characteristics of breast cancer in China and its shift during 1999-2008: A national-wide multicenter cross-sectional image over 10 years[J]. Int J Cancer, 2012, 131(11):2622-2631.
【3】HART CD, SANNA G, SICLARI O, et al. Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes[J]. Breast, 2015, 24 Suppl 2:S136-S142.
【4】ALLGOOD PC, DUFFY SW, KEARINS O, et al. Explaining the difference in prognosis between screen-detected and symptomatic breast cancers[J]. Br J Cancer, 2011, 104(11):1680-1685.
【5】JOENSUU H, PYLKK?NEN L, TOIKKANEN S. Late mortality from pT1N0M0 breast carcinoma[J]. Cancer, 1999, 85(10):2183-2189.
【6】HANRAHAN EO, GONZALEZANGULO AM, GIORDANO SH, et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma[J]. J Clin Oncol, 2007, 25(31):4952-4960.
【7】FISHER B, DIGNAM J, TANCHIU E, et al. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes[J]. J Natl Cancer Inst, 2001, 93(2):112-120.
【8】KENNEDY T, STEWART AK, BILIMORIA KY, et al. Treatment trends and factors associated with survival in T1aN0 and T1bN0 breast cancer patients[J]. Ann Surg Oncol, 2007, 14(10):2918-2927.
【9】SCHROEDER MC, LYNCH CF, ABU-HEJLEH T, et al. Chemotherapy use and surgical treatment by receptor subtype in node-negative T1a and T1b female breast cancers, Iowa SEER Registry, 2010-2012[J]. Clin Breast Cancer, 2015, 15(1):e27-e34.
【10】IGNATOV T, EGGEMANN H, BURGER E, et al. Management of small T1a/b breast cancer by tumor subtype[J]. Breast Cancer Res Treat, 2017, 163(1):1-8.
【11】Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100?000 women in 123 randomised trials[J]. Lancet, 2012, 379(9814):432-444.
【12】HOUVENAEGHEL G, GONCALVES A, CLASSE JM, et al. Characteristics and clinical outcome of T1 breast cancer: A multicenter retrospective cohort study[J]. Ann Oncol, 2014, 25(3):623-628.
【13】CHIA SK, SPEERS CH, BRYCE CJ, et al. Ten-year outcomes in a opulation-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies[J]. J Clin Oncol, 2004, 22 (9):1630-1637.
【14】GAMUCCI T, VACCARO A, CIANCOLA F, et al. Recurrence risk in small, node-negative, early breast cancer: A multicenter retrospective analysis[J]. J Cancer Res Clin Oncol, 2013, 139(5):853-860.
【15】李军楠, 刘晓东, 佟仲生. T1micN0M0、T1aN0M0和T1bN0M0乳腺癌376例临床特征和预后分析[J]. 肿瘤, 2011, 31(11):1026-1030.
【16】AZAMBUJA ED, CARDOSO F, CASTRO GD, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients[J]. Br J Cancer, 2007, 96(10):1504-1513.
【2】ZHENG S, BAI JQ, LI J, et al. The pathologic characteristics of breast cancer in China and its shift during 1999-2008: A national-wide multicenter cross-sectional image over 10 years[J]. Int J Cancer, 2012, 131(11):2622-2631.
【3】HART CD, SANNA G, SICLARI O, et al. Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes[J]. Breast, 2015, 24 Suppl 2:S136-S142.
【4】ALLGOOD PC, DUFFY SW, KEARINS O, et al. Explaining the difference in prognosis between screen-detected and symptomatic breast cancers[J]. Br J Cancer, 2011, 104(11):1680-1685.
【5】JOENSUU H, PYLKK?NEN L, TOIKKANEN S. Late mortality from pT1N0M0 breast carcinoma[J]. Cancer, 1999, 85(10):2183-2189.
【6】HANRAHAN EO, GONZALEZANGULO AM, GIORDANO SH, et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma[J]. J Clin Oncol, 2007, 25(31):4952-4960.
【7】FISHER B, DIGNAM J, TANCHIU E, et al. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes[J]. J Natl Cancer Inst, 2001, 93(2):112-120.
【8】KENNEDY T, STEWART AK, BILIMORIA KY, et al. Treatment trends and factors associated with survival in T1aN0 and T1bN0 breast cancer patients[J]. Ann Surg Oncol, 2007, 14(10):2918-2927.
【9】SCHROEDER MC, LYNCH CF, ABU-HEJLEH T, et al. Chemotherapy use and surgical treatment by receptor subtype in node-negative T1a and T1b female breast cancers, Iowa SEER Registry, 2010-2012[J]. Clin Breast Cancer, 2015, 15(1):e27-e34.
【10】IGNATOV T, EGGEMANN H, BURGER E, et al. Management of small T1a/b breast cancer by tumor subtype[J]. Breast Cancer Res Treat, 2017, 163(1):1-8.
【11】Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100?000 women in 123 randomised trials[J]. Lancet, 2012, 379(9814):432-444.
【12】HOUVENAEGHEL G, GONCALVES A, CLASSE JM, et al. Characteristics and clinical outcome of T1 breast cancer: A multicenter retrospective cohort study[J]. Ann Oncol, 2014, 25(3):623-628.
【13】CHIA SK, SPEERS CH, BRYCE CJ, et al. Ten-year outcomes in a opulation-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies[J]. J Clin Oncol, 2004, 22 (9):1630-1637.
【14】GAMUCCI T, VACCARO A, CIANCOLA F, et al. Recurrence risk in small, node-negative, early breast cancer: A multicenter retrospective analysis[J]. J Cancer Res Clin Oncol, 2013, 139(5):853-860.
【15】李军楠, 刘晓东, 佟仲生. T1micN0M0、T1aN0M0和T1bN0M0乳腺癌376例临床特征和预后分析[J]. 肿瘤, 2011, 31(11):1026-1030.
【16】AZAMBUJA ED, CARDOSO F, CASTRO GD, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients[J]. Br J Cancer, 2007, 96(10):1504-1513.
相关信息